ProMIS Neurosciences Auf den Markt gebrachte Aktien

Was ist das Auf den Markt gebrachte Aktien von ProMIS Neurosciences?

Auf den Markt gebrachte Aktien von ProMIS Neurosciences, Inc. ist 6.750M 1.56%

Was ist die Definition von Auf den Markt gebrachte Aktien?

Der Aktien-Float- Anteil ist der Anteil der Aktien einer Gesellschaft, der sich in der Hand öffentlicher Investoren befindet, im Gegensatz zu den gesperrten Stücken

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

Was macht ProMIS Neurosciences?

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Unternehmen mit auf den markt gebrachte aktien ähnlich ProMIS Neurosciences

  • BioVie hat Auf den Markt gebrachte Aktien von 6.734M 26.97%
  • BioVie hat Auf den Markt gebrachte Aktien von 6.734M 26.97%
  • BioVie hat Auf den Markt gebrachte Aktien von 6.734M 26.97%
  • u-blox AG hat Auf den Markt gebrachte Aktien von 6.739M 96.45%
  • Jerrick Media hat Auf den Markt gebrachte Aktien von 6.739M 66.65%
  • Sanco Industries hat Auf den Markt gebrachte Aktien von 6.748M 65.62%
  • ProMIS Neurosciences hat Auf den Markt gebrachte Aktien von 6.750M 1.56%
  • Lux Industries hat Auf den Markt gebrachte Aktien von 6.754M 22.46%
  • INEOS Styrolution India hat Auf den Markt gebrachte Aktien von 6.769M 38.49%
  • Emmbi Industries hat Auf den Markt gebrachte Aktien von 6.769M 38.27%
  • VerifyMe hat Auf den Markt gebrachte Aktien von 6.779M 92.89%
  • Cineline India hat Auf den Markt gebrachte Aktien von 6.783M 24.22%
  • Creative Eye hat Auf den Markt gebrachte Aktien von 6.783M 33.82%